Patents by Inventor John Allingham

John Allingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytotoxic actin-targeting compounds
    Patent number: 12239639
    Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 4, 2025
    Assignee: Queen's University at Kingston
    Inventors: Rebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
  • Cytotoxic Actin-Targeting Compounds
    Publication number: 20230037322
    Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
    Type: Application
    Filed: June 27, 2022
    Publication date: February 9, 2023
    Inventors: Rebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
  • Cytotoxic actin-targeting compounds
    Patent number: 11369594
    Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: June 28, 2022
    Assignee: Queen's University at Kingston
    Inventors: Rebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
  • Cytotoxic Actin-Targeting Compounds
    Publication number: 20200306233
    Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
    Type: Application
    Filed: August 17, 2018
    Publication date: October 1, 2020
    Inventors: Rebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
  • Beverage mug
    Patent number: D544305
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: June 12, 2007
    Inventor: Richard John Allingham